Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non–Small-Cell Lung Cancer
Clinical Lung Cancer · 2023-11 · 24 (7) · 651-659
DOI: 10.1016/j.cllc.2023.08.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lung Cancer, 2023-11. Verfasst von Maryam Ebadi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Washington, Seattle, WA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiosurgery. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND PURPOSE: The role of stereotactic body radiation therapy (SBRT) in oligoprogressive non-small-cell lung cancer (NSCLC) is controversial. We evaluated whether SBRT in a subset of patients with oligoprogressive or oligorecurrent NSCLC offers a durable response, obviating the need to change systemic therapy. METHODS: A retrospective analysis of 168 NSCLC patients who underwent SBRT for oligoprogressive or oligorecurrent disease was performed. Oligoprogression was defined as progression in ≤5 lesions during or after systemic therapy following an initial complete or partial response. Oligorecurrence was defined as progression while off systemic therapy. Progression-free survival (PFS), overall survival (OS) and time to next treatment or death (TNT-D) were estimated. RESULTS: Median age was 68 years. Sixty-seven percent of patients were on systemic therapy at the time of progression. Progression at the primary site was present in 31% of the patients. The number of sites of metastatic progression was 0 to 2 in 76% and 3 to 5 in 24% of the patients. Two-year OS and PFS were 56% (95%CI 46%-64%) and 14% (95%CI 8%-21%), respectively. Median TNT-D was 9 months (95%CI 6-11). No grade 4 or 5 toxicity was seen. In multivariable analysis, patients with 3 to 5 sites of metastatic progression had worse OS (HR 2.6, 95%CI 1.5-4.3, P < .001) and shorter TNT-D (HR 1.7, 95%CI 1.1-2.5, P = .01) than those with 0 to 2 sites. CONCLUSION: SBRT is a safe and viable treatment option for oligoprogressive and oligorecurrent NSCLC. Patients with 0 to 2 sites had better OS and longer TNT-D compared to those with 3 to 5 lesions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Washington, Seattle, WA.
- Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, CA.
- Department of Medical Oncology & Therapeutics Research, City of Hope National Cancer Center, Duarte, CA.
- Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, CA. Electronic address: aamini@coh.org.
Zitieren
APA
Ebadi, M., Ladbury, C., Liu, J., Rock, A., Onyshchenko, M., Villaflor, V., Villalona-Calero, M., Salgia, R., Massarelli, E., Lee, P., Williams, T., & Amini, A. (2023). Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 24(7), 651-659. https://doi.org/10.1016/j.cllc.2023.08.015
Vancouver
Ebadi M, Ladbury C, Liu J, Rock A, Onyshchenko M, Villaflor V, et al. Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 2023;24(7):651-659. doi:10.1016/j.cllc.2023.08.015
BibTeX
@article{Ebadi2023,
author = {Ebadi, Maryam and Ladbury, Colton and Liu, Jason and Rock, Adam and Onyshchenko, Mykola and Villaflor, Victoria and Villalona-Calero, Miguel and Salgia, Ravi and Massarelli, Erminia and Lee, Percy and Williams, Terence and Amini, Arya},
title = {Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non–Small-Cell Lung Cancer},
journal = {Clinical Lung Cancer},
year = {2023},
volume = {24},
number = {7},
pages = {651--659},
doi = {10.1016/j.cllc.2023.08.015}
}
EUVIMED